



DOCKET NO.: DUP-0307

GAU 1616  
BOX D 2 WND  
PATENT  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 03 2000

RECEIVED

TECH CENTER 1600/2900

In Re Application of:

APR 28 2000

Evan C. Unger, DeKang Shen  
and Guanli Wu

TECH CENTER 1600/2900

Serial No.: 09/218,660

Group Art Unit: 1616

Filing Date: December 22, 1998

Examiner: S. Sharareh

For: NOVEL METHODS TARGETED COMPOSITIONS FOR DIAGNOSTIC  
AND THERAPEUTIC USE

DATE OF DEPOSIT: 4/17/00

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE ASSISTANT COMMISSIONER  
FOR PATENTS, WASHINGTON, DC 20231.

S. Maurice Valla  
REGISTRATION NO.: 43,966

Box  NON-FEE

AF

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- A Response to Notice to Comply with Sequence Listing Requirements dated January 12, 2000.

RECEIVED

APR 28 2000

DOCKET NO.: DUP-0307

- 2 -

TECH CENTER 1600/2900

PATENT MAY 03 2000

An Amendment Supplemental to the Paper filed \_\_\_\_\_ TECH CENTER 1600/2900

Other: Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821 Through 1.825; paper and computer readable copies of the Sequence Listing

Small entity status of this application under 37 C.F.R. 1.9 and 1.27 was established in a previous submission.

A Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed.

This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.

Substitute Pages \_\_\_\_\_ of the Specification are enclosed.

An Abstract is enclosed.

\_\_\_\_\_ Sheets of Proposed Corrected Drawings are enclosed.

A Certified Copy of each of the following applications: \_\_\_\_\_ is enclosed.

An Associate Power of Attorney is enclosed.

Information Disclosure Statement.  
 Attached Form 1449.  
 A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.

Appended Material as follows: \_\_\_\_\_

Other Material as follows: \_\_\_\_\_

## FEE CALCULATION

No Additional Fee is Due.

			SMALL ENTITY		NOT SMALL ENTITY		
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	Fee	RATE	Fee
TOTAL CLAIMS		(20 MINIMUM)		\$9 EACH	\$	\$18 EACH	\$
INDEP. CLAIMS		(3 MINIMUM)		\$39 EACH	\$	\$78 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$130	\$	\$260	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
<input checked="" type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$190	\$190.00	\$380	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$435	\$	\$870	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$680	\$	\$1360	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$925	\$	\$1850	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$ )	minus	(\$ )
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$190.00		\$

- A Check is Enclosed in the Foregoing Amount Due.
- Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Notice to Comply with Sequence Listing Requirements of **January 12, 2000** to and through **April 12, 2000** comprising an extension of the shortened statutory period of **two (2) month(s)**.
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-

identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

The Forgoing Amount Due for Filing this Paper.

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

**SHOULD ANY DEFICIENCIES APPEAR** with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 4/12/00

  
\_\_\_\_\_  
S. Maurice Valla  
Registration No. 43,966

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



Application No.: 09/218,660

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**